07:16:33 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-02-07 Bokslutskommuniké 2023
2023-11-08 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-06-08 Årsstämma 2023
2023-05-31 Kvartalsrapport 2023-Q1
2023-05-10 Ordinarie utdelning IDOGEN 0.00 SEK
2023-02-24 Bokslutskommuniké 2022
2022-12-13 Extra Bolagsstämma 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-05 Ordinarie utdelning IDOGEN 0.00 SEK
2022-05-04 Kvartalsrapport 2022-Q1
2022-05-04 Årsstämma 2022
2022-01-19 Bokslutskommuniké 2021
2021-10-26 Kvartalsrapport 2021-Q3
2021-08-24 Kvartalsrapport 2021-Q2
2021-05-12 Ordinarie utdelning IDOGEN 0.00 SEK
2021-05-12 Kvartalsrapport 2021-Q1
2021-05-11 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-11-04 Extra Bolagsstämma 2020
2020-10-23 Kvartalsrapport 2020-Q3
2020-08-25 Kvartalsrapport 2020-Q2
2020-05-27 Split IDOGEN 10:1
2020-05-13 Ordinarie utdelning IDOGEN 0.00 SEK
2020-05-12 Kvartalsrapport 2020-Q1
2020-05-12 Årsstämma 2020
2020-01-29 Bokslutskommuniké 2019
2019-10-22 Kvartalsrapport 2019-Q3
2019-08-20 Kvartalsrapport 2019-Q2
2019-06-26 Ordinarie utdelning IDOGEN 0.00 SEK
2019-06-25 Årsstämma 2019
2019-04-29 Kvartalsrapport 2019-Q1
2019-02-06 Bokslutskommuniké 2018
2018-10-23 Kvartalsrapport 2018-Q3
2018-08-21 Kvartalsrapport 2018-Q2
2018-04-25 Ordinarie utdelning IDOGEN 0.00 SEK
2018-04-24 Årsstämma 2018
2018-04-24 Kvartalsrapport 2018-Q1
2018-02-06 Bokslutskommuniké 2017
2017-10-26 Kvartalsrapport 2017-Q3
2017-08-30 Kvartalsrapport 2017-Q2
2017-05-18 Ordinarie utdelning IDOGEN 0.00 SEK
2017-05-17 Årsstämma 2017
2017-04-24 Kvartalsrapport 2017-Q1
2017-02-15 Bokslutskommuniké 2016
2016-11-11 Kvartalsrapport 2016-Q3
2016-08-26 Kvartalsrapport 2016-Q2
2016-04-26 Kvartalsrapport 2016-Q1
2016-04-26 Årsstämma 2016
2016-02-18 Ordinarie utdelning IDOGEN 0.00 SEK
2016-02-17 Bokslutskommuniké 2015
2015-10-29 Kvartalsrapport 2015-Q3
2015-08-27 Kvartalsrapport 2015-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Idogen är verksamma inom bioteknik. Bolagets affärsinriktning är att utveckla vaccinkandidater för behandling av sjukdomar som negativt påverkar immunförsvaret. Vaccinen avses att användas i de fall där det uppkommit autoimmuna sjukdomar och efter organavstötning, särskilt vid de fall där de bildats antikroppar mot intagningen av patientens ordinarie läkemedel. Bolaget grundades under 2008 och har sitt huvudkontor i Lund.
2023-02-24 12:04:00

Idogen AB's interim report for January to December 2022 is available on the company's website https://idogen.com/en/investors/financial-reports/

Fourth quarter (October-December 2022)
  • Other operating income amounted to KSEK 256 (3,335)

  • Operating loss was KSEK -11,759 (-13,552)

  • Loss for the quarter totaled KSEK -11,465 (-13,529)

  • Cash flow from operating activities was KSEK -12,591 (-15,074)

  • Loss per share before dilution was SEK -0.16 (-0.61). Loss per share after dilution was SEK -0.16 (-0.61)

  • The proposed dividend is SEK 0.00/share (0.00)

Period (January-December 2022)
  • Other operating income amounted to KSEK 414 (13,915)

  • Operating loss was KSEK -47,972 (-38,965)

  • Loss for the quarter totaled KSEK -47,750 (-38,854)

  • Cash flow from operating activities was KSEK -50,703 (-40,190)

  • Loss per share before dilution was SEK -0.76 (-2.02). Loss per share after dilution was SEK -0.76 (-2.02)

Significant events in the fourth quarter
  • First patient is included in Norway.

  • Idogen's Idogen sharpens focus on its IDO 8 program, pauses the IDO T and IDO programs and lowers operating expenditure.

  • Idogen receives after exercise of warrants 280 KSEK before costs.

  • First patient enters Idogen's hemophilia study under the IDO 8 program.

  • EU to disburse the remaining of the Horizon 2020 grant.

  • Agneta Edberg elected as new Chairman of Idogen due to changes to the Board of Directors.

  • The board of Idogen propose a rights issue at up to 38 MSEK net after cost.

  • Idogen invites for an extra shareholder meeting 13 December

Significant events in the period
  • Idogen submits an application for clinical trial with IDO 8 to the Norwegian Medicines Agency, NoMA.

  • Idogens presented the company's tolerogenic cell therapy platform at the 5th Antigen-Specific Immune

Tolerance Summit.
  • Idogen enters into an agreement with Vator Securities AB regarding the assignment as Certified Adviser from May 15.

  • Idogen's rights issue raise MSEK 41 after issue costs.

  • Idogen receives approval from the Swedish Medical Products Agency to start its clinical phase 1/2a study

for IDO 8.
  • Idogen's rights issue raise MSEK 41 after issue costs.

  • Idogen receives approval from the Swedish Medical Products Agency to start its clinical phase 1/2a study for IDO 8.

  • Idogen strengthens the organization with key competencies for the clinical development phase.

  • Idogen brings together scientific advisors at the ISTH 2022 scientific conference in London.

  • Idogen receives approval from the Norwegian Medicines Agency, NoMA, for a clinical phase 1/2a study with the IDO 8-program.

  • An extraordinary general meeting of shareholders on September 6 elected Joakim Söderström as new

chairman and Niklas Wallet as a new member of the Board of Directors.
  • Christina Herder is appointed acting CEO after Anders Karlsson.
Significant events after the end of the period
  • New issue gives proceed of net 5.3 MSEK after costs.

  • Idogen invited by GJCF to participate in their 3rd Summit for NMOSD Tolerization

  • Idogen will pause the clinical trial in the IDO 8 program as the company currently do not have sufficient capital

  • No other significant events occurred after the end of the period that affected the results or financial position.

For further information, please contact:

Christina Herder, Acting CEO, Idogen AB

Tel: +46 70374 71 56

E-mail: christina.herder@idogen.com

Certified Adviser:
Vator Securities AB

The information was submitted for publication, through the agency of the contact persons set out above, on February 24, 2023 at 12:04 CET.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.